-
2022-502882-53-00
6
2025-03-03
HIV-1
-
2024-510719-31-00
5
2025-01-24
Moderate to Severe Vasomotor Symptoms (VMS)
-
2023-504192-25-00
6
2024-06-05
HIV-1
-
2023-508359-38-00
5
2024-06-05
Early-stage Non-squamous Non-small Cell Lung Cancer
-
2022-502099-22-01
5
2024-04-29
HIV-1 Infection
-
2023-504993-40-00
5
2024-02-14
Human immunodeficiency virus (HIV)
-
2023-503265-27-00
5
2023-11-23
Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co
-
2023-503544-13-00
9
2023-11-02
Polycythemia Vera
-
2022-502593-17-00
5
2023-09-19
Locally advanced or metastatic hormone receptor (HR)-positive, human e
-
2022-502779-40-00
5
2023-09-04
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2022-501024-20-00
5
2023-07-25
ER+/HER2- Early Breast Cancer
-
2024-512359-19-00
4
2023-05-12
Resectable Non-small cell lung cancer Pancoast tumor
-
2022-501463-40-01
5
2023-05-03
Locally Advanced or Metastatic Cholangiocarcinoma
-
2023-505552-22-00
5
2023-02-24
Stage I-III Triple-negative Breast Cancer with residual invasive disea
-
2024-518486-10-00
4
2023-02-23
Non-Muscle Invasive Bladder Cancer
-
2023-508498-97-00
5
2023-02-03
Systemic Lupus Erythematosus
-
2024-510970-26-00
4
2022-11-28
Metastatic pancreatic cancer
-
2024-514630-21-00
4
2022-08-11
HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Bre
-
2023-510097-14-00
5
2022-04-15
Patients with MMR deficient relapse or advanced / metastatic endometri
-
2023-509406-30-00
10
2022-01-24
Patients with HER2-overexpressing advanced or metastatic gastric or ga
-
2023-508723-12-00
5
2021-09-27
gastroenteropancreatic neuroendocrine tumors
-
2023-507132-21-00
10
2021-05-11
Early Parkinson's disease
-
2023-503568-18-00
5
2021-04-13
Early human epidermal growth factor receptor 2 (HER2) positive breast
-
2023-509405-77-00
5
2021-02-16
Colorectal cancer (BRAF V600E-mutant mCRC)